Адаланк

Тиз җавап

Reliable Adalank peptide supplied by professional manufacturer and factory. Offer wholesale modified Selank peptides for neuroscience, stress regulation and cognitive enhancement laboratory research.

Adalank is a synthetic peptide analogue of selank, with targeted chemical alteration.

 

 

Мәхәббәтегезне бүлешегез

Adalank is a synthetic peptide analogue of selank, with targeted chemical alteration.

The peptide is designed as a тудыру .әр сүзнең nootropic drug Selank, with the addition of an acetylated N-terminal function that enhances its adamantane-like sterically-constraining structure.

This modification acts as a powerful synergistic potentiator of the anxiolytic – nootropic compound Selank.

It circumvents Selank’s poor кан-ми барьеры (BBB) penetration, thereby increasing the үзәк нерв системасы activity of Adalank significantly.

The addition of an acetyl group eliminates the positive charge of the N-terminal free amino group and decreases the net charge of the peptide.

This physicochemical adjustment optimizes the изоэлектрик нокта and surface properties of Adalank, reducing non-specific electrostatic interactions.

Нәтиҗәдә, the drug molecule crosses the blood–brain barrier more easily and reaches the central nervous system.

Моннан тыш, ацетиляция protects Adalank from exopeptidase degradation and significantly increases its in vivo half-life.

This provides the advantage of prolonged therapeutic blood levels and reduces frequent dosing.

The inclusion of adamantane creates a stable “conformation core” in the Adalank peptide.

This imparts a fixed spatial orientation to the initially flexible linear peptide, promoting the stereochemical conformation necessary for biological activity even in its unbound state.

This greatly improves Adalank’s ability to cross the blood-brain barrier.

Моннан тыш, Adalank exhibits certain immunomodulatory effects.

Эзлек

ac-thr-lys-pro-arg-pro-gly-pro-Adamantane-nh2

CAS номеры

/

Молекуляр формула

C46H75N13O10

Молекуляр авырлык

970.19

Research Of Adalank:

1.Эш механизмы

Efficacy-wise, Adalank’s rigid structure more closely corresponds to the allosteric modulation site of the GABA_A receptor alpha subunit, imparting stronger ансиколитик effects.

Моннан тыш, the adamantane moiety enables hydrophobic interactions in the NMDA receptor channel area to moderate calcium influx and protect against excitotoxic injury.

This property has the potential for нейропротекция in models of ischemic brain injury and post-traumatic stress disorder (ПТСД).

2.Anxiolytic Effects

As an optimized derivative of Selank, Adalank maintains a high-affinity interaction with the benzodiazepine site on the GABA_A receptor α-subunit.

Ләкин, the N-terminal acetylation and adamantane scaffold shift the binding mode from “flexible induced fit” to “rigid precise docking”.

This enhances GABAergic inhibitory neurotransmission, promoting chloride influx and rapid reduction of activity in hyperactive amygdala-prefrontal cortex neural circuits.

In contrast to benzodiazepines, Adalank shows high receptor subtype selectivity, enabling sustained anxiolytic effects without the sedation, muscle relaxation, or addiction potential associated with traditional drugs.

Its therapeutic index is 3 to 5 times wider, supporting long-term management of generalized anxiety disorder and situational anxiety disorders.

3.Cognitive Enhancement and Memory Improvement

Adalank effectively inhibits the activation of the NF-κB inflammatory pathway and increases BDNF mRNA expression by 50%-80% .әр сүзнең иппокампус.

This leads to activation of downstream Akt/CREB signaling pathways, facilitating LTP induction and maintenance.

It significantly improves memory retention in passive avoidance тестлар, enhances spatial learning in the Моррис су лабиринты, and counteracts scopolamine-induced cholinergic damage.

Preclinical data indicate that Adalank reduces working memory errors by 40%-60% and mitigates natural memory decline in aged animals, suggesting applicability in learning disorders, mild cognitive impairment, and age-related memory decline.

4.Нейропротив эффектлар

The adamantane structure in Adalank mimics the action of memantine, acting as a non-competitive NMDA receptor antagonist that causes voltage-dependent blockade of open channels and physiological regulation of calcium influx.

It reduces pathological Ca²⁺ influx by 60–70% without impairing physiological synaptic Ca²⁺ signaling, achieving a selective neuroprotective profile without disrupting normal function.

Шулай итеп, preclinical studies highlight Adalank’s significant translational potential for early intervention in acute stroke, spinal cord injury, һәм нейродженератив авырулар.

COA

HPLC

МС

(1) Без телибез, C.. Р.; Белый, C.. М.. Гамма-аминобутир кислотасы рецепторларына тәэсир итүче седатив-гипнотик агентлар: Флунитразепамга игътибар итегез, Гамма-Гидроксибутир кислотасы, Фенибут, һәм Селанк. J Клиник Фармакол 2021, 61 Өстәмә 2, S114-S128. DOI: 10.1002/jcph.1922 From NLM M

(2) Начар нәрсә, A.; Коломин, Т.; Андреева, Л.; Бондаренко, Э.; Мясоедов, Н.; Сломинский, П.; Шадрина, М.. Пептид Селанк Диазепамның тычканнардагы көтелмәгән хроник йомшак стресс шартларында борчылуны киметүдә тәэсирен көчәйтә.. Бехав Нейрол 2017, 2017, 50910

(3) Пин, Л.. Г.; Надорова, А.. V.; Антипова, Т.. A.; Круглов, С.. V.; Кудрин, V.. С.; Дурнев, А.. D.. Селанк, Туфцинның пептид аналогы, Protects Against Ethanol-Induced Memory Impairment by Regulating of BDNF Content in the Hippocampus and Prefrontal Cortex

(4) Пин, Л.. Г.; Надорова, А.. V.; Серененин, С.. Б.. Селанк Этанолга китерелгән гиперлокомонияне һәм DBA / 2 тычканнарында үз-үзеңне тотышка сизгерлекне тыя.. Bull Exp Biol Med 2016, 162 (1), 56-59. DOI: 10.1007/s10517-016-3544-6 NLM Medlineдан.

(5) Бәясе, N.. V.; Соколов, О.; Габаева, М.. V.; Гривенников, Мин. A.; Андреева, Л.. A.; Миаседов, N.. Ф.; Зозулия, А.. А.. [Семакс һәм селанк энкефалинны киметүче ферментларны кеше зарарыннан тыя]]. Биорг Хим 2001, 27 (3), 180-183. DOI: 10.1023/а:10113730028

(6) Белмим, Г.. Г.; Телешова, E.. С.; Бохкарев, V.. К.; Кощелев, V.. V.; Сюняков, Т.. С.. P.3.036 Роман ансиколитик Селанк: Фаза II клиник сынаулары нәтиҗәләре. Европа нейропсихофармакологиясе 2005, 15, S159-S160. DOI: 10.1016/s0924-977x(05)80332-3.

(7) Сломинский, Б.. A.; Шадрина, М.. I.; Коломин, Т.. A.; Ставровская, А.. V.; Филатова, E.. V.; Андреева, Л.. A.; Илариошкин, С.. Н.; Мясоедов, N.. F.. Пептидлар семакс һәм селанк 6-OHDA белән тычканнарның тәртибенә тәэсир итәләр, ПД сыман паркинсонизм. Dokl Biol Sc

(8) Соллертинская, Т.. Н.; Шорохов, М.. V.; Мясоедов, N.. F.. Семакс һәм Селанкның церебропротив эффектлары төрле нейроз приматларында. Халыкара психофизиология журналы 2008, 69 (3). DOI: 10.1016/j.ijpsycho.2008.05.356.

Эзлек:

ac-thr-lys-pro-arg-pro-gly-pro-Adamantane-nh2

CAS:

N / A.

М.В.:

970.19 g / mol

Өй Эзләү Ватсап Хезмәтләр Продукция